2023-07-11 15:30:55
medicine
Tuesday, July 11, 2023 Milan – The administration of the beta-lactam antibiotic meropenem as a continuous infusion does not appear to have any advantage for sepsis patients treated in the intensive care unit, at least not in terms of mortality and the development of antibiotic resistance. This is shown by the results of a randomized controlled study presented by an international research group in JAMA (2023; DOI: 10.1001/jama.2023.10598)….
1689116283
#Continuous #intermittent #meropenem #not..
